Comparable endemic coronavirus nucleoprotein-specific antibodies in mild and severe Covid-19 patients.
JSON
Leach S, Harandi AM, Bergström T, Andersson LM, Nilsson S, van der Hoek L, Gisslén M
J Med Virol 93 (9) 5614-5617
[2021-09-00; online 2021-05-03]
The severity of disease of Covid-19 is highly variable, ranging from asymptomatic to critical respiratory disease and death. Potential cross-reactive immune responses between SARS-CoV-2 and endemic coronavirus (eCoV) may hypothetically contribute to this variability. We herein studied if eCoV nucleoprotein (N)-specific antibodies in the sera of patients with mild or severe Covid-19 are associated with Covid-19 severity. There were comparable levels of eCoV N-specific antibodies early and during the first month of infection in Covid-19 patients with mild and severe symptoms, and healthy SARS-CoV-2-negative subjects. These results warrant further studies to investigate the potential role of eCoV-specific antibodies in immunity to SARS-CoV-2 infection.
Funder: KAW/SciLifeLab National COVID program
Research Area: Biobanks for COVID-19 research
PubMed 33913546
DOI 10.1002/jmv.27038
Crossref 10.1002/jmv.27038